Hohimer Wealth Management LLC Buys 1,146 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Hohimer Wealth Management LLC grew its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 54.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,269 shares of the pharmaceutical company’s stock after buying an additional 1,146 shares during the period. Hohimer Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $1,280,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in VRTX. Police & Firemen s Retirement System of New Jersey increased its holdings in Vertex Pharmaceuticals by 3.7% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 39,035 shares of the pharmaceutical company’s stock valued at $17,378,000 after buying an additional 1,393 shares during the period. Bailard Inc. boosted its position in shares of Vertex Pharmaceuticals by 0.5% during the 2nd quarter. Bailard Inc. now owns 38,147 shares of the pharmaceutical company’s stock valued at $16,983,000 after acquiring an additional 200 shares in the last quarter. Leuthold Group LLC bought a new stake in Vertex Pharmaceuticals in the third quarter valued at about $5,030,000. Advisory Resource Group acquired a new position in Vertex Pharmaceuticals in the third quarter worth about $1,286,000. Finally, Generali Asset Management SPA SGR raised its position in Vertex Pharmaceuticals by 41.8% in the third quarter. Generali Asset Management SPA SGR now owns 23,569 shares of the pharmaceutical company’s stock worth $9,231,000 after purchasing an additional 6,942 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on VRTX shares. Scotiabank lifted their price objective on Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a report on Friday, February 13th. Stifel Nicolaus boosted their price target on Vertex Pharmaceuticals from $445.00 to $466.00 and gave the company a “hold” rating in a research note on Friday, February 13th. Wolfe Research upgraded Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 price target on the stock in a research report on Tuesday, January 6th. Wells Fargo & Company increased their price objective on Vertex Pharmaceuticals from $460.00 to $515.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Finally, Royal Bank Of Canada reduced their target price on shares of Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating on the stock in a research note on Friday, February 13th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $542.00.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 260 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total value of $126,451.00. Following the completion of the sale, the executive vice president owned 46,763 shares of the company’s stock, valued at $22,743,185.05. This trade represents a 0.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Amit Sachdev sold 1,846 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total transaction of $897,802.10. Following the completion of the transaction, the executive vice president owned 55,570 shares of the company’s stock, valued at $27,026,469.50. This trade represents a 3.22% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 168,937 shares of company stock worth $77,879,922. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $496.83 on Friday. The business’s fifty day moving average is $466.55 and its two-hundred day moving average is $431.98. The firm has a market cap of $126.21 billion, a P/E ratio of 32.41 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The business had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the business posted $3.98 earnings per share. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Clinical safety expansion — Vertex announced a new study to evaluate VX‑548 (an investigational pain drug) in breastfeeding women, broadening the drug’s safety profile and de‑risking development pathways if results are supportive. Vertex Expands VX‑548 Safety Profile With New Breastfeeding Study
• Positive Sentiment: Leadership/PR tailwind — TIME profiled CEO Reshma Kewalramani, reinforcing investor confidence in management’s execution and Vertex’s strategy to expand beyond cystic fibrosis. Physician‑Scientist Reshma Kewalramani Runs One of Biotech’s Biggest Companies
• Positive Sentiment: Analyst support — recent upgrades and raised price targets (several firms highlighted in coverage) help underpin the stock and attract buy‑side interest. MarketBeat VRTX analyst coverage
• Neutral Sentiment: Quarterly fundamentals — Q4 revenue rose ~9.5% y/y and margins remain strong, though EPS missed by $0.02 (reported $5.03 vs. $5.05 consensus); this is a small miss that keeps the longer‑term thesis intact but mutes near‑term upside. Vertex recent earnings summary
• Neutral Sentiment: Momentum/coverage — pieces asking whether VRTX is outperforming major indices may draw momentum flows but do not represent new fundamental catalysts. Is Vertex Stock Outperforming the Dow?
• Negative Sentiment: Clustered insider selling — multiple senior executives disclosed sales between Feb. 19–25, including a large sale by EVP Amit Sachdev (~58,613 shares, ~ $27.5M) and several other EVPs reducing positions. Such concentrated insider sales can create near‑term negative sentiment even if driven by diversification or tax planning. Representative SEC filing: SEC Form 4 – Amit Sachdev
• Negative Sentiment: Additional officer sale — CAO Kristen Ambrose sold 223 shares (minor relative to the EVP sales) but is part of the broader disclosure set that traders are reacting to. Vertex insider sales roundup

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.